HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED

Share ownership Hansoh Pharmaceutical Group Company Limited

3692

KYG549581067

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 09:08:11 17/07/2026 BST			5-day change	1st Jan Change
31.80 ^HKD	-4.10%		+2.05%	-11.86%

07-14	Avery Therapeutics, Inc. announced that it has received $320 million in funding from a group of investors	CI
07-13	Avere Therapeutics, Inc. announced that it expects to receive $69 million in funding from a group of investors	CI

Share class: Hansoh Pharmaceutical Group Company Limited

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	6,065,344,717	1,239,743,040 ( 20.44 %)	1,194,647 ( 0.0197 %)	20.44 %

Major shareholders: Hansoh Pharmaceutical Group Company Limited

Name	Stocks	%	Valuation
Yu An Sun 64.35 %	3,902,214,583	64.35 %	14 739 M $
Jun Da Cen 15.17 %	920,000,000	15.17 %	3 475 M $
Fidelity Management & Research (Hong Kong) Ltd. 0.6448 %	39,100,000	0.6448 %	148 M $
Yinhua Fund Management Co., Ltd. 0.2908 %	17,632,000	0.2908 %	67 M $
China Asset Management Co., Ltd. 0.1815 %	11,008,000	0.1815 %	42 M $
ICBC UBS Asset Management Co. Ltd. 0.1714 %	10,394,000	0.1714 %	39 M $
UBS Asset Management (Hong Kong) Ltd. 0.1681 %	10,193,481	0.1681 %	39 M $
Bank of China Investment Management Co., Ltd. 0.1623 %	9,844,635	0.1623 %	37 M $
Invesco Great Wall Fund Management Co. Ltd. 0.0934 %	5,666,000	0.0934 %	21 M $
Fullgoal Fund Management Co., Ltd. 0.093 %	5,638,640	0.093 %	21 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Individuals	79.54%
Institutional	2.6%
Unknown	17.86%

Based on 1000 largest holdings

Geographical origin of shareholders

Individuals	79.55%
China	1.37%
Hong Kong	0.95%
United Kingdom	0.1%
United States	0.06%
Ireland	0.02%
Luxembourg	0.02%
New Zealand	0.01%
Switzerland	0.01%
Italy	0.01%
Singapore	0.01%
France	0.01%
Netherlands	0.01%
Canada	0.01%

Based on 1000 largest holdings

Hansoh Pharmaceutical Group Company Ltd is an investment holding company primarily engaged in the research and development, production and sale of a series of pharmaceutical products. The Companyâ€™s innovative drug products include Ameile, Hansoh Xinfu, Mailingda, Fulaimei, Hengmu, XINYUE, Saint Luolai and other products. The Companyâ€™s drug products are mainly used in oncology, anti-infective diseases, central nervous system (CNS) diseases, metabolic diseases and other therapeutic areas. The Company mainly conducts its business in the domestic market.

Employees

9,347

Sector

Pharmaceuticals

More about the company